Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Brief Summary: the aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or 24 weeks in combination with PegIFN/RBV given for 24-48 weeks, according to re-randomisation of Early Treatment Success (ETS) patients at 24 weeks to stop PegIFN/RBV or continue PegIFN/RBV until week 48. If no ETS, then PegIFN/RB for 48 weeks, in HCV treatment-naive or relapsers patients coinfected with HIV


Options:
A: Arm Label: BI201335 12W; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: BI201335 | Arm Label: BI 201335 24W; Type: EXPERIMENTAL; Interventions: Drug: BI201335 24W, Drug: PegIFN/RBV | Arm Label: BI 201335 24 W; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: Bi 201335 | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 24 W | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI201335 12W | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): BI201335 12W | Intervention Type: DRUG; Name: BI201335 24W; Assigned to Arm(s): BI 201335 24W | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 24W | Intervention Type: DRUG; Name: Bi 201335; Assigned to Arm(s): BI 201335 24 W
B: Arm Label: Arm 1 (Control Arm); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Biological: Peginterferon alfa-2a, Drug: Ribavirin | Arm Label: Arm 2 (Boceprevir Arm); Type: EXPERIMENTAL; Interventions: Drug: Boceprevir, Biological: Peginterferon alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): Arm 2 (Boceprevir Arm) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm 1 (Control Arm) | Intervention Type: BIOLOGICAL; Name: Peginterferon alfa-2a; Assigned to Arm(s): Arm 1 (Control Arm), Arm 2 (Boceprevir Arm) | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Arm 1 (Control Arm), Arm 2 (Boceprevir Arm)
C: Arm Label: 20mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 48mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 120mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 240mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 240mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 120mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 48mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 20mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm C

Answer: A